Isoindole Derivative Small Molecule IgE Inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IgE-related diseases, such as eczema and asthma, often rely on protein-based therapies like Omalizumab, which are complex, costly, and have immunogenicity concerns, while small-molecular inhibitors are sought for better safety and efficacy.
Innovation Solution
Development of a compound of formula (I) and its stereoisomers, which are used in pharmaceutical compositions to treat IgE-mediated diseases, involving a process that includes reacting a compound with malonic acid and ammonium acetate, followed by esterification and further reactions to obtain the active compound.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-based therapies like Omalizumab are used to treat IgE-related diseases, then therapeutic efficacy is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent creates small-molecule compounds that copy the therapeutic function of protein-based IgE inhibitors. Instead of using complex proteins like Omalizumab, the invention synthesizes simpler molecular structures (formula I compounds) that can bind to and inhibit IgE, achieving similar therapeutic effects with much simpler manufacturing processes
Solution Approach 2:
The patent employs small-molecule compounds that are cheaper to produce and manufacture compared to protein-based therapies. These small molecules can be synthesized through standard chemical processes rather than requiring complex biomanufacturing, reducing both manufacturing complexity and cost while maintaining therapeutic efficacy
2Reliability
If protein-based therapies like Omalizumab are used to treat IgE-related diseases, then therapeutic efficacy is improved, but production cost increases
Solution Approach 1:
The patent creates small-molecule compounds that copy the therapeutic function of protein-based IgE inhibitors. Instead of using complex proteins like Omalizumab, the invention synthesizes simpler molecular structures (formula I compounds) that can bind to and inhibit IgE, achieving similar therapeutic effects with much simpler manufacturing processes
Solution Approach 2:
The patent employs small-molecule compounds that are cheaper to produce and manufacture compared to protein-based therapies. These small molecules can be synthesized through standard chemical processes rather than requiring complex biomanufacturing, reducing both manufacturing complexity and cost while maintaining therapeutic efficacy
3Reliability
If protein-based therapies like Omalizumab are used to treat IgE-related diseases, then therapeutic efficacy is improved, but immunogenicity risks increase
Solution Approach 1:
The patent creates small-molecule compounds that copy the therapeutic function of protein-based IgE inhibitors. Instead of using complex proteins like Omalizumab, the invention synthesizes simpler molecular structures (formula I compounds) that can bind to and inhibit IgE, achieving similar therapeutic effects with much simpler manufacturing processes
Solution Approach 2:
The patent employs small-molecule compounds that are cheaper to produce and manufacture compared to protein-based therapies. These small molecules can be synthesized through standard chemical processes rather than requiring complex biomanufacturing, reducing both manufacturing complexity and cost while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively reduces IgE levels, thereby decreasing inflammation and improving symptoms in IgE-related diseases like eczema and asthma, offering a safer and more cost-effective alternative to existing treatments.
Implementation Method 1
After the external antigen binds to IgE, it promotes the increase of eosinophilia in blood through two ways: (1) Antigen binds to IgE receptors on mast cells and stimulates the mast cells to release eosinophilic chemokines.
Data Source
AI summary
Disclosed is a compound of formula (I) and a stereoisomer thereof:wherein R1, R2, R3 and R4 are as defined in the present disclosure.